Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
HUTCHMED said the first patient received the first dose in China on Sept. 24 in its Phase Ia global trial of HMPL-A830 in unresectable, advanced or metastatic solid tumors. The company also said a GSK subsidiary has worldwide rights outside Greater China under a Sept. 3 agreement, subject to customary closing condition
First-in-class KRAS-payload leveraging synchronized EGFR inhibitionHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase Ia part of a global c…